In which patients with SSc do you add anti-platelet therapy and/or statins for Raynaud's phenomenon?

We believe that platelet aggregation plays some role in the development of digital ulcers, but we don't have any trial data to support the use of antiplatelet agents. But for patients who have recurrent digital tip ulcerations despite vasodilators, I will consider the use of antiplatelet agents (81 ...

The evidence for antiplatelet therapy and statins for RP is not strong, mainly owing to the challenges we would face trying to develop a trial that would demonstrate a net benefit of such treatments in a controlled setting. In clinical practice, I consider adding these agents in as adjunct therapies...

For patients with the development of gangrene or signs of ongoing vascular ischemia in spite of maximum vasodilator medications, I add antiplatelet medication.

Statins are left to PCP if concurrent dyslipidemia and/or cardiac or stroke risk factors.